LAVA THERAPEUTICS N.V. |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2.75 USD | -2.83% |
|
-12.14% | +74.06% |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration
LAVA Therapeutics NV, formerly known as Lava Therapeutics BV, is a provider of biotechnology research and development services based in the Netherlands. The Company focuses of developing next generation Vdelta T cell engaging bispecific antibodies to fight cancer.
Calendar
2024-05-14
- Q1 2024 Earnings Release (Projected)
Sell
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
2.654
EUR
Average target price
6.684
EUR
Spread / Average Target
+151.84%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +74.06% | 74.4M | |
| -1.49% | 41.35B | |
| +41.59% | 40.38B | |
| +3.36% | 39.05B | |
| -12.11% | 26.67B | |
| +1.97% | 24.07B | |
| -23.47% | 18.36B | |
| -3.37% | 11.68B | |
| +21.26% | 11.6B | |
| +7.54% | 11.15B |
- Stock Market
- Equities
- LVTX Stock
- News LAVA Therapeutics N.V.
- Lava Therapeutics Says FDA Clears IND Application for Lava-051 to Treat Leukemia, Other Diseases; Shares Rise
